Vaniprevir
- Generic Name
- Vaniprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C38H55N5O9S
- CAS Number
- 923590-37-8
- Unique Ingredient Identifier
- CV3X74AO1H
- Background
Vaniprevir has been used in trials studying the treatment and diagnostic of Hepatitis C, Chronic Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C Infection, and Chronic Genotype 1 Hepatitis C Virus Infection.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 51
- Registration Number
- NCT01405937
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT01405560
Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 294
- Registration Number
- NCT01370642
Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3
- Registration Number
- NCT00954993
A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00880763
Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 285
- Registration Number
- NCT00704405
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath